79 results on '"Alcusky, M."'
Search Results
2. CO48 To Treat or Not to Treat: Comparing Oral Anticoagulant Outcomes Among U.S. Nursing Home Residents with Atrial Fibrillation
- Author
-
Chen, Q., primary, Lapane, K.L., additional, Tjia, J., additional, Goldberg, R., additional, Baek, J., additional, and Alcusky, M., additional
- Published
- 2023
- Full Text
- View/download PDF
3. PIH21 Impact of Medical Home Implementation on Potentially Inappropriate Medication Use Among Older Adults: A Longitudinal Population-Based Study in Parma, Italy
- Author
-
Chen, A., primary, Molaei, M., additional, Jafari, N., additional, Keith, S.W., additional, Alcusky, M., additional, Lombardi, M., additional, Pini, M., additional, and Maio, V., additional
- Published
- 2021
- Full Text
- View/download PDF
4. PDB25 The Medical Homes Initiative in Italy: An Analysis of Processes of Care in Diabetes
- Author
-
Patel, S., primary, Jafari, N., additional, Keith, S.W., additional, Alcusky, M., additional, Hegarty, S.E., additional, Lombardi, M., additional, Pini, M., additional, and Maio, V., additional
- Published
- 2021
- Full Text
- View/download PDF
5. PIH24 Medical Home Implementation Reduced Inappropriate Medication Use Among Older Adults in Parma, Italy: Does Early Adoption and Duration of Experience Matter?
- Author
-
Molaei, M., primary, Chen, A., additional, Jafari, N., additional, Keith, S.W., additional, Alcusky, M., additional, Lombardi, M., additional, Pini, M., additional, and Maio, V., additional
- Published
- 2021
- Full Text
- View/download PDF
6. RWD149 Real-World Comparison of Cardiovascular Benefits between Sodium-Glucose Cotransporter 2 (SGLT-2I) and Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Inhibitors in Patients with Type 2 Diabetes (T2D)
- Author
-
Huang, D., Greenwood, B., Salsabili, M., Tesell, M., and Alcusky, M.
- Published
- 2023
- Full Text
- View/download PDF
7. EPH165 Geographic Variation of Antidementia Medication Use Among U.S. Nursing Home Residents with Dementia
- Author
-
Rataj, A., Alcusky, M., Ott, B., Baek, J., and Lapane, K.L.
- Published
- 2023
- Full Text
- View/download PDF
8. EPH111 Changes in Antidementia Medications at Admission to the Nursing Home: Who Decides and Why? Results from a National Survey
- Author
-
Liang, S., Lapane, K.L., Ott, B., and Alcusky, M.
- Published
- 2023
- Full Text
- View/download PDF
9. PNS106 MEDICAL HOME IMPLEMENTATION AND HEALTHCARE UTILIZATION: A LONGITUDINAL ANALYSIS IN ITALY
- Author
-
Waters, D.D., primary, Alcusky, M., additional, Hegarty, S.E., additional, Jafari, N., additional, Keith, S.W., additional, Lombardi, M., additional, Pini, M., additional, and Maio, V., additional
- Published
- 2020
- Full Text
- View/download PDF
10. PDG46 PREVALENCE AND PREDICTORS OF POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING FOR ELDERLY PATIENTS: A POPULATION-BASED CROSS-SECTIONAL STUDY
- Author
-
Shelley, K., primary, Kee, A., additional, Jafari, N., additional, Alcusky, M., additional, Lombardi, M., additional, Keith, S.W., additional, and Maio, V., additional
- Published
- 2019
- Full Text
- View/download PDF
11. PNS59 EFFECTS OF AN INTERVENTION TO REDUCE INAPPROPRIATE PRESCRIBING ON HOSPITALIZATION RATES IN A LARGE POPULATION OF OLDER ADULTS
- Author
-
Kee, A., primary, Alcusky, M., additional, Shelley, K., additional, Jafari, N., additional, Del Canale, S., additional, Lombardi, M., additional, Keith, S.W., additional, and Maio, V., additional
- Published
- 2019
- Full Text
- View/download PDF
12. Variation In Locoregional Treatment Of Stage I – II Breast Cancer By Breast Subtype In Nonelderly Adult Women
- Author
-
Voelker, J, primary, Alcusky, M, additional, Singer, D, additional, Mitchell, E, additional, and Delgado, D, additional
- Published
- 2018
- Full Text
- View/download PDF
13. Do Medical Homes Affect Healthcare Utilization Rates? A Longitudinal Evaluation on Medical Home Implementation in Italy
- Author
-
Voelker, J, primary, Hegarty, SE, additional, Keith, SW, additional, Alcusky, M, additional, Lombardi, M, additional, and Maio, V, additional
- Published
- 2018
- Full Text
- View/download PDF
14. TREATMENT OF ATRIAL FIBRILLATION IN NURSING HOMES: A PLACE FOR DIRECT ACTING ORAL ANTICOAGULANTS?
- Author
-
Alcusky, M., primary and Lapane, K.L., additional
- Published
- 2018
- Full Text
- View/download PDF
15. Did a Physician-Targeted Intervention that Reduced Potentially Inappropriate Prescribing to Elderly Patients also Reduce Related Hospitalizations?
- Author
-
McRae, J, primary, Hegarty, SE, additional, Alcusky, M, additional, Vegesna, A, additional, Varga, S, additional, Keith, SW, additional, Del Canale, S, additional, Lombardi, M, additional, and Maio, V, additional
- Published
- 2016
- Full Text
- View/download PDF
16. STATED AND DERIVED PREFERENCES OF TREATMENT ATTRIBUTES IN MODERATE-SEVERE PSORIASIS PATIENTS
- Author
-
Lee, S., primary, Alcusky, M., additional, Chiu, G.R., additional, Deshpande, A., additional, Fleming, S., additional, Hadker, N., additional, Lau, G., additional, and Vance, N., additional
- Published
- 2016
- Full Text
- View/download PDF
17. PHS91 - Do Medical Homes Affect Healthcare Utilization Rates? A Longitudinal Evaluation on Medical Home Implementation in Italy
- Author
-
Voelker, J, Hegarty, SE, Keith, SW, Alcusky, M, Lombardi, M, and Maio, V
- Published
- 2018
- Full Text
- View/download PDF
18. PCN177 - Variation In Locoregional Treatment Of Stage I – II Breast Cancer By Breast Subtype In Nonelderly Adult Women
- Author
-
Voelker, J, Alcusky, M, Singer, D, Mitchell, E, and Delgado, D
- Published
- 2018
- Full Text
- View/download PDF
19. PIH53 - Did a Physician-Targeted Intervention that Reduced Potentially Inappropriate Prescribing to Elderly Patients also Reduce Related Hospitalizations?
- Author
-
McRae, J, Hegarty, SE, Alcusky, M, Vegesna, A, Varga, S, Keith, SW, Del Canale, S, Lombardi, M, and Maio, V
- Published
- 2016
- Full Text
- View/download PDF
20. PSY67 - STATED AND DERIVED PREFERENCES OF TREATMENT ATTRIBUTES IN MODERATE-SEVERE PSORIASIS PATIENTS
- Author
-
Lee, S., Alcusky, M., Chiu, G.R., Deshpande, A., Fleming, S., Hadker, N., Lau, G., and Vance, N.
- Published
- 2016
- Full Text
- View/download PDF
21. Geographic Variation of Antidementia and Antipsychotic Medication Use Among US Nursing Home Residents With Dementia.
- Author
-
Rataj A, Alcusky M, Baek J, Ott B, and Lapane KL
- Subjects
- Humans, United States, Male, Female, Aged, 80 and over, Aged, Medicare statistics & numerical data, Nursing Homes statistics & numerical data, Antipsychotic Agents therapeutic use, Dementia drug therapy, Cholinesterase Inhibitors therapeutic use, Memantine therapeutic use
- Abstract
Background: Several antidementia medications have been approved for symptomatic treatment of cognitive and functional impairment due to Alzheimer disease. Antipsychotics are often prescribed off-label for behavioral symptoms., Objective: The aim of this study was to describe the basis for regional variation in antidementia and antipsychotic medication use., Setting: US nursing homes (n=9735), hospital referral regions (HRR; n=289)., Subjects: Long-stay residents with dementia (n=273,004)., Methods: Using 2018 Minimum Data Set 3.0 linked to Medicare data, facility information, and Dartmouth Atlas files, we calculated prevalence of use and separate multilevel logistic models [outcomes: memantine, cholinesterase inhibitor (ChEI), antipsychotic use] estimated adjusted odds ratios (aOR) and 95% CIs for resident, facility, and HRR characteristics. We then fit a series of cross-classified multilevel logistic models to estimate the proportional change in cluster variance (PCV)., Results: Overall, 20.9% used antipsychotics, 16.1% used memantine, and 23.3% used ChEIs. For antipsychotics, facility factors [eg, use of physical restraints (aOR: 1.08; 95% CI: 1.05-1.11) or poor staffing ratings (aOR: 1.10; 95% CI: 1.06-1.14)] were associated with more antipsychotic use. Nursing homes in HRRs with the highest health care utilization had greater antidementia drug use (aOR memantine: 1.68; 95% CI: 1.44-1.96). Resident/facility factors accounted for much regional variation in antipsychotics (PCV STATE : 27.80%; PCV HRR : 39.54%). For antidementia medications, HRR-level factors accounted for most regional variation (memantine PCV STATE : 37.44%; ChEI PCV STATE : 39.02%)., Conclusion: Regional variations exist in antipsychotic and antidementia medication use among nursing home residents with dementia suggesting the need for evidence-based protocols to guide the use of these medications., Competing Interests: K.L.L. is a consultant to Exponent to provide guidance on data resources for an NIA funded nursing home co-operative initiative. The remaining authors declare no conflicts of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
22. To treat or not to treat: a comparative effectiveness analysis of oral anticoagulant outcomes among U.S. nursing home residents with atrial fibrillation.
- Author
-
Chen Q, Baek J, Goldberg R, Tjia J, Lapane K, and Alcusky M
- Subjects
- Humans, Male, Female, Aged, United States epidemiology, Retrospective Studies, Aged, 80 and over, Administration, Oral, Medicare trends, Treatment Outcome, Ischemic Stroke epidemiology, Ischemic Stroke prevention & control, Cohort Studies, Comparative Effectiveness Research, Hemorrhage chemically induced, Hemorrhage epidemiology, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Nursing Homes trends
- Abstract
Background: Nursing home residents with atrial fibrillation are at high risk for ischemic stroke, but most are not treated with anticoagulants. This study compared the effectiveness and safety between oral anticoagulant (OAC) users and non-users., Methods: We conducted a new-user retrospective cohort study by using Minimum Data Set 3.0 assessments linked with Medicare claims. The participants were Medicare fee-for-service beneficiaries with atrial fibrillation residing in US nursing homes between 2011 and 2016, aged ≥ 65 years. The primary outcomes were occurrence of an ischemic stroke or systemic embolism (effectiveness), occurrence of intracranial or extracranial bleeding (safety) and net clinical outcome (effectiveness or safety outcomes). Secondary outcomes included total mortality and a net clinical and mortality outcome. Cox proportional hazards and Fine and Grey models estimated multivariable adjusted hazard ratios (aHRs) and sub-distribution hazard ratios (sHRs)., Results: Outcome rates were low (effectiveness: OAC: 0.86; non-users: 1.73; safety: OAC: 2.26; non-users: 1.75 (per 100 person-years)). OAC use was associated with a lower rate of the effectiveness outcome (sHR: 0.69; 95% Confidence Interval (CI): 0.61-0.77), higher rates of the safety (sHR: 1.70; 95% CI: 1.58-1.84) and net clinical outcomes (sHR: 1.20; 95% CI: 1.13-1.28) lower rate of all-cause mortality outcome (sHR: 0.60; 95% CI: 0.59-0.61), and lower rate of the net clinical and mortality outcome (sHR: 0.60; 95% CI: 0.59-0.61). Warfarin users, but not DOAC users, had a higher rate of the net clinical outcome versus OAC non-users., Conclusions: Our results support the benefits of treatment with OACs to prevent ischemic strokes and increase longevity, while highlighting the need to weigh apparent benefits against elevated risk for bleeding. Results were consistent with net favorability of DOACs versus warfarin., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Antidementia Medication Use in Nursing Home Residents.
- Author
-
Ott BR, Hollins C, Tjia J, Baek J, Chen Q, Lapane KL, and Alcusky M
- Subjects
- Humans, Nursing Homes, Cholinesterase Inhibitors therapeutic use, Cognition, Memantine therapeutic use, Alzheimer Disease drug therapy
- Abstract
Background: Antidementia medication can provide symptomatic improvements in patients with Alzheimer's disease, but there is a lack of consensus guidance on when to start and stop treatment in the nursing home setting., Methods: We describe utilization patterns of cholinesterase inhibitors (ChEI) and memantine for 3,50,197 newly admitted NH residents with dementia between 2011 and 2018., Results: Overall, pre-admission use of antidementia medications declined from 2011 to 2018 (ChEIs: 44.5% to 36.9%; memantine: 27.4% to 23.2%). Older age, use of a feeding tube, and greater functional dependency were associated with lower odds of ChEI initiation. Coronary artery disease, parenteral nutrition, severe aggressive behaviors, severe cognitive impairment, and high functional dependency were associated with discontinuation of ChEIs. Comparison of clinical factors related to anti-dementia drug treatment changes from pre to post NH admission in 2011 and 2018 revealed a change toward lower likelihood of initiation of treatment among residents with more functional dependency and those with indicators of more complex illness as well as a change toward higher likelihood of discontinuation in residents having 2 or more hospital stays., Conclusions: These prescribing trends highlight the need for additional research on the effects of initiating and discontinuing antidementia medications in the NH to provide clear guidance for clinicians when making treatment decisions for individual residents., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
24. Practice Site Heterogeneity within and between Medicaid Accountable Care Organizations.
- Author
-
Dyer Z, Alcusky M, Himmelstein J, Ash A, and Kerrissey M
- Abstract
The existing literature has considered accountable care organizations (ACOs) as whole entities, neglecting potentially important variations in the characteristics and experiences of the individual practice sites that comprise them. In this observational cross-sectional study, our aim is to characterize the experience, capacity, and process heterogeneity at the practice site level within and between Medicaid ACOs, drawing on the Massachusetts Medicaid and Children's Health Insurance Program (MassHealth), which launched an ACO reform effort in 2018. We used a 2019 survey of a representative sample of administrators from practice sites participating in Medicaid ACOs in Massachusetts ( n = 225). We quantified the clustering of responses by practice site within all 17 Medicaid ACOs in Massachusetts for measures of process change, previous experience with alternative payment models, and changes in the practices' ability to deliver high-quality care. Using multilevel logistic models, we calculated median odds ratios (MORs) and intraclass correlation coefficients (ICCs) to quantify the variation within and between ACOs for each measure. We found greater heterogeneity within the ACOs than between them for all measures, regardless of practice site and ACO characteristics (all ICCs ≤ 0.26). Our research indicates diverse experience with, and capacity for, implementing ACO initiatives across practice sites in Medicaid ACOs. Future research and program design should account for characteristics of practice sites within ACOs.
- Published
- 2024
- Full Text
- View/download PDF
25. Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators.
- Author
-
Lapane KL, Ott BR, Hargraves JL, Cosenza C, Liang S, and Alcusky M
- Subjects
- Humans, Aged, Nursing Homes, Skilled Nursing Facilities, Hospitalization, Dementia psychology
- Abstract
Objective: Little is known about who is involved and what factors influence changes in antidementia medications for older adults living in nursing homes. The study sought to describe factors associated with initiation and discontinuation of antidementia medications in nursing home residents with dementia., Design: National survey of nursing homes with ≥30 beds; homes with dementia units were oversampled., Settings and Participants: Nursing home administrators [eg, Directors of Nursing (DoNs)]., Methods: In 2022, 1293 homes were surveyed (response rate: 26.6%, n = 340). Weighted analyses provided nationally representative results corrected for nonresponse (n = 14,455)., Results: DoNs reported that people always/almost always involved in antidementia medication decisions included nursing home prescriber (84.4%), nursing staff (33.2%), family (23.4%), resident (13.8%), community primary care provider (12.1%), and dementia specialist (5.8%). DoNs reported that antidementia medications were much more likely to be initiated if residents (55.8%) and family members (53.2%) wanted antidementia medications, a dementia specialist was involved (51.9%), resident had aggressive behaviors (44.8%), resisted care (31.6%), or had severe physical/cognitive impairment (22.3%). DoNs reported that antidementia medications were much more likely to be discontinued with dementia specialist involvement (46.5%), progression to severe impairment (39.2%), hospice involvement (31.5%), <6 months' prognosis (28.5%), emergence of aggressive behaviors (25.2%), or resisting care (19.0%) and much less likely to be discontinued if residents (30.2%) and family (27.3%) were reluctant to discontinue. One in 6 homes reported that residents had no immediate family/caregivers usually or almost always/always., Conclusions and Implications: DoNs report that family/caregivers and dementia specialists have significant influence on antidementia medication decisions in nursing homes, but many residents lack their involvement. Real-world evidence on the risks and benefits of antidementia medications in nursing homes is needed to inform clinical guidance about appropriate use of antidementia medications in nursing homes., Competing Interests: Disclosure Dr Lapane is a consultant to Exponent on an NIH-funded nursing home initiative (Long Term Care Data Collaborative). Her work as a consultant was not related to this study. The other authors declare no conflicts of interest., (Copyright © 2023 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Trade-offs in locational choices for care coordination resources in accountable care organizations.
- Author
-
Tsuei SH, Alcusky M, Florio C, and Kerrissey MJ
- Subjects
- United States, Humans, Cross-Sectional Studies, Medicaid, Quality Improvement, Quality of Health Care, Accountable Care Organizations
- Abstract
Background: Care coordination is central to accountable care organizations (ACOs), especially in Medicaid where many patients have complex medical and social needs. Little is known about how to best organize care coordination resources in this context, particularly whether to centralize them. We examined how care coordinators' location, management, and colocation of both (within ACO headquarters, practice sites, or other organizations) relate to care quality and coordination., Methods: We conducted a cross-sectional analysis of surveys administered to a sample of practice sites covering all 17 Medicaid ACOs in Massachusetts ( n = 225, response rate = 64%). We applied controlled, cluster-robust regressions, adjusting the significance threshold for the number of ACO clusters, to assess how clinical information sharing across settings, care quality improvement, knowledge of social service referral, and cross-resource coordination (i.e., the ability of multiple resources to work well together) relate to where care coordinators were physically located and/or managed., Results: Centralizing care coordinators at ACO headquarters was associated with greater information sharing. Embedding care coordinators in practices was associated with greater care quality improvement. Embedding coordinators at other organizations was associated with less information sharing and care quality improvement. Managing coordinators at practice sites and other organizations were associated with better care quality improvement and cross-resource coordination, respectively. Colocating the two functions showed no significant differences., Practice Implications: Choosing care coordinators' locations may present trade-offs. ACOs may strategically choose embedding care coordinators at practice sites for enhanced care quality versus centralizing them at the ACO to facilitate information sharing., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
27. Facilitators and Barriers to Care Coordination Between Medicaid Accountable Care Organizations and Community Partners: Early Lessons From Massachusetts.
- Author
-
Kachoria AG, Sefton L, Miller F, Leary A, Goff SL, Nicholson J, Himmelstein J, and Alcusky M
- Subjects
- United States, Humans, Massachusetts, Health Care Reform, Health Services Accessibility, Medicaid, Accountable Care Organizations
- Abstract
Care coordination is central to health care delivery system reform efforts to control costs, improve quality, and enhance patient outcomes, especially for individuals with complex medical and social needs. The potential impact of addressing health-related social needs further illustrates the importance of coordinating health care services with community-based organizations that provide social services and support. This study offers early findings from a unique approach to care coordination delivered by 17 Medicaid Accountable Care Organizations and 27 partnering community-based organizations for individuals with behavioral health conditions and/or those needing long-term services and supports. Interview data from 54 key informants were qualitatively analyzed to understand factors affecting cross-sector integrated care. Key themes emerged, essential to implementing the new model statewide: clarifying roles and responsibilities; promoting communication; facilitating information exchange; developing workforce capacity; building essential relationships; and responsive, supportive program management through real-time feedback, financial incentives, technical assistance, and flexibility from the state Medicaid program.
- Published
- 2023
- Full Text
- View/download PDF
28. Integration on the Frontlines of Medicaid Accountable Care Organizations and Associations With Perceived Care Quality, Health Equity, and Satisfaction.
- Author
-
Kerrissey M, Jamakandi S, Alcusky M, Himmelstein J, and Rosenthal M
- Subjects
- United States, Humans, Medicaid, Quality of Health Care, Personal Satisfaction, Accountable Care Organizations, Health Equity
- Abstract
Amid enthusiasm about accountable care organizations (ACOs) in Medicaid, little is known about the primary care practices engaging in them. We leverage a survey of administrators within a random sample (stratified by ACO) of 225 practices joining Massachusetts Medicaid ACOs (64% response rate; 225 responses). We measure the integration of processes with distinct entities: consulting clinicians, eye specialists for diabetes care, mental/behavioral care providers, and long-term and social services agencies. Using multivariable regression, we examine organizational correlates of integration and assess integration's relationships with care quality improvement, health equity, and satisfaction with the ACO. Integration varied across practices. Clinical integration was positively associated with perceived care quality improvement; social service integration was positively associated with addressing equity; and mental/behavioral and long-term service integration were positively associated with ACO satisfaction (all p < .05). Understanding differences in integration at the practice level is vital for sharpening policy, setting expectations, and supporting improvement in Medicaid ACOs.
- Published
- 2023
- Full Text
- View/download PDF
29. Discontinuation of oral anticoagulant use among nursing home residents with atrial fibrillation before hospice enrollment.
- Author
-
Chen Q, Baek J, Goldberg R, Tjia J, Lapane K, and Alcusky M
- Subjects
- Humans, Aged, United States epidemiology, Anticoagulants therapeutic use, Cross-Sectional Studies, Nursing Homes, Medicare, Administration, Oral, Retrospective Studies, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Hospice Care, Hospices, Stroke prevention & control, Stroke drug therapy
- Abstract
Background: Oral anticoagulants (OACs) are effective in reducing the risk of cardioembolic stroke due to atrial fibrillation. While most nursing home residents with atrial fibrillation qualify for anticoagulation based on clinical guidelines, the net clinical benefits of OACs may diminish as residents approach the end of life., Methods: We conducted a cross-sectional study of 30,503 US nursing home residents with atrial fibrillation (based on Minimum Data Set 3.0 and Medicare Part A records) who used OACs in the year before enrolling in hospice care during 2012-2016. Whether residents discontinued OACs before hospice enrollment was determined using Part D claims and date of hospice enrollment. Modified Poisson models estimated adjusted prevalence ratios (aPR)., Results: Almost half (45.7%) of residents who had recent OAC use discontinued prior to hospice enrollment. Residents who were underweight (aPR: 1.02; 95% confidence interval [CI]: 1.01-1.03), those with high bleeding risk (aPR: 1.04, 95% CI: 1.03-1.05), and those with moderate or severe cognitive impairment (aPR: 1.02, 95% CI: 1.02-1.03) had a higher prevalence of OAC discontinuation before entering hospice. Residents with venous thromboembolism (aPR: 0.94, 95% CI: 0.93-0.96), statin users (aPR: 0.88, 95% CI: 0.87-0.89), and those on polypharmacy (≥10 medications, aPR: 0.72; 95% CI: 0.71-0.73) were less likely to discontinue OACs before enrollment in hospice., Conclusion: Anticoagulants are often discontinued among older nursing home residents with atrial fibrillation before hospice enrollment; it is not clear that these decisions are driven solely by net clinical benefit considerations. Further research is needed on comparative outcomes to inform resident-centered decisions regarding OAC use in older adults entering hospice., (© 2023 The American Geriatrics Society.)
- Published
- 2023
- Full Text
- View/download PDF
30. Prescription digital therapeutics: Applying Medicaid experience to value assessment and formulary management.
- Author
-
Salsabili M, Tesell M, Alcusky M, Greenwood BC, Huang D, Lenz K, and Dave J
- Subjects
- United States, Humans, Massachusetts, Medicaid, Prescriptions
- Abstract
Digital therapeutics (DTx) are a rapidly growing therapeutic category with more than 150 clinical trials evaluating US Food and Drug Administration-regulated DTx to develop additional evidence by the end of 2022. Investments in DTx development have doubled since 2019, reaching $14.7 billion in 2021. Prescription DTx are regulated by the US Food and Drug Administration and require demonstration of efficacy and safety prior to commercialization and reimbursement by payers. Drawing insights from the Massachusetts Medicaid program's early experience with prescription DTx, we provide an overview of this new category of therapeutics and suggest a roadmap for payers and policymakers to evaluate the value of prescription DTx for their member population. Finally, we propose solutions to potential challenges that may be encountered in the DTx coverage and reimbursement management.
- Published
- 2023
- Full Text
- View/download PDF
31. Perspectives on deprescribing in palliative care.
- Author
-
Tjia J, Karakida M, Alcusky M, and Furuno JP
- Subjects
- Humans, Palliative Care, Pharmacists, Communication, Deprescriptions, Physicians
- Abstract
Introduction: Pharmacotherapy plays a critical role in the delivery of high-quality palliative care, but the intersection of palliative care and deprescribing has received little attention., Areas Covered: We conducted a scoping review of English language articles using PubMed to identify relevant publications between 1 January 2000 to 31 July 2022 using search terms of deprescribing, palliative care, end of life, and hospice. We summarize current definitions and developments in palliative care and deprescribing from both clinical and research perspectives. We highlight key challenges and outline proposed solutions and needed research., Expert Opinion: The future of deprescribing in palliative care requires the development and adoption of individualized approaches to medication management, including a reconsidered approach to communication about deprescribing. Evidence from high-quality clinical outcomes studies is lacking, and the field needs new approaches to coordination of care delivery. This review article will be of interest to both clinical and research-based pharmacists, physicians, and nurses interested in improving care for patients with serious illness.
- Published
- 2023
- Full Text
- View/download PDF
32. Psychosocial Data: A Pillar of Integrated and Accountable Care Systems.
- Author
-
Alcusky M
- Subjects
- Humans, United States, Medicare, Social Responsibility, Accountable Care Organizations, Delivery of Health Care, Integrated
- Abstract
Competing Interests: The author declares no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
33. Paper of Association of Social Determinants of Health With Adherence to Second-generation Antipsychotics for People With Bipolar Disorders in a Medicaid Population.
- Author
-
Li NC, Alcusky M, Masters GA, and Ash A
- Subjects
- Humans, Medicaid, Medication Adherence, Social Determinants of Health, United States, Antipsychotic Agents therapeutic use, Bipolar Disorder drug therapy
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
34. The Medical Home Initiative in Italy: an Analysis of Changes in Healthcare Utilization.
- Author
-
Keith SW, Waters D, Alcusky M, Hegarty S, Jafari N, Lombardi M, Pini M, and Maio V
- Subjects
- Emergency Service, Hospital, Humans, Longitudinal Studies, Patient Acceptance of Health Care, Patient-Centered Care, Hospitalization, Pulmonary Disease, Chronic Obstructive
- Abstract
Background: Seventeen medical homes (MHs) were established in the Local Health Authority (LHA) of Parma (about 450,000 residents), Emilia Romagna, Italy, between 2011 and 2016., Objective: To estimate the effects of MH implementation on healthcare utilization., Design: We conducted a longitudinal cohort study (01/2011-12/2017) using the Parma LHA administrative healthcare database., Participants: Residents for ≥1 year and older than 14 years of age with a documented primary care physician (PCP) in Parma LHA., Intervention: MH exposure status was classified for each resident as either receiving care from a PCP that (1) eventually practices in an MH (pre-MH), (2) is currently in an MH (post-MH), or (3) does not join an MH (non-MH)., Main Outcome Measures: Risks of ordinary inpatient hospital admissions, day hospital admissions, admissions for ambulatory care sensitive conditions (ACSCs), all-cause emergency department (ED) visits, and deferrable ED visits were compared using Cox proportional hazards regression and risks of all-cause 30- and 90-day readmissions for congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) were compared using logistic regression., Key Results: Prior to MH implementation, the risk of all-cause ED visits for pre-MH residents was 0.93 (95% CI: 0.92-0.94) that of non-MH residents. After MH implementation, the relative risk for post-MH versus non-MH was 0.86 (95% CI: 0.85-0.87) and, over time, post-MH versus pre-MH was 0.93 (95% CI: 0.92-0.94). Hospitalization risks were generally lower among the pre-MH and post-MH, compared to non-MH. However, hospitalizations and HF or COPD readmissions were not generally lower post-MH compared to pre-MH., Conclusions: This MH initiative was associated with a 7% reduction in risk of ED visits. More research is necessary to understand if ED visit risk will continue to improve and how other aspects of healthcare utilization might change as more MHs open and the length of exposure to MHs increases., (© 2021. Society of General Internal Medicine.)
- Published
- 2022
- Full Text
- View/download PDF
35. Angiotensin blockade therapy and survival in pancreatic cancer: a population study.
- Author
-
Keith SW, Maio V, Arafat HA, Alcusky M, Karagiannis T, Rabinowitz C, Lavu H, and Louis DZ
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Pancreatic Neoplasms drug therapy, Proportional Hazards Models, Survival Rate, Treatment Outcome, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Pancreatic Neoplasms mortality
- Abstract
Background: Pancreatic cancer (PC) is one of the most aggressive and challenging cancer types to effectively treat, ranking as the fourth-leading cause of cancer death in the United States. We investigated if exposures to angiotensin II receptor blockers (ARBs) or angiotensin I converting enzyme (ACE) inhibitors after PC diagnosis are associated with survival., Methods: PC patients were identified by ICD-9 diagnosis and procedure codes among the 3.7 million adults living in the Emilia-Romagna Region from their administrative health care database containing patient data on demographics, hospital discharges, all-cause mortality, and outpatient pharmacy prescriptions. Cox modeling estimated covariate-adjusted mortality hazard ratios for time-dependent ARB and ACE inhibitor exposures after PC diagnosis., Results: 8,158 incident PC patients were identified between 2003 and 2011, among whom 20% had pancreas resection surgery, 36% were diagnosed with metastatic disease, and 7,027 (86%) died by December 2012. Compared to otherwise similar patients, those exposed to ARBs after PC diagnosis experienced 20% lower mortality risk (HR=0.80; 95% CI: 0.72, 0.89). Those exposed to ACE inhibitors during the first three years of survival after PC diagnosis experienced 13% lower mortality risk (HR=0.87; 95% CI: 0.80, 0.94) which attenuated after surviving three years (HR=1.14; 95% CI: 0.90, 1.45)., Conclusions: The results of this large population study suggest that exposures to ARBs and ACE inhibitors after PC diagnosis are significantly associated with improved survival. ARBs and ACE inhibitors could be important considerations for treating PC patients, particularly those with the worst prognosis and most limited treatment options. Considering that these common FDA approved drugs are inexpensive to payers and present minimal increased risk of adverse events to patients, there is an urgent need for randomized clinical trials, large simple randomized trials, or pragmatic clinical trials to formally and broadly evaluate the effects of ARBs and ACE inhibitors on survival in PC patients., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
36. Association of Social Determinants of Health With Adherence to Second-generation Antipsychotics for People With Bipolar Disorders in a Medicaid Population.
- Author
-
Li NC, Alcusky M, Masters GA, and Ash AS
- Subjects
- Adolescent, Adult, Antipsychotic Agents administration & dosage, Cross-Sectional Studies, Female, Humans, Insurance Claim Review, Male, Medicaid statistics & numerical data, Middle Aged, Residence Characteristics, Socioeconomic Factors, United States, Young Adult, Antipsychotic Agents therapeutic use, Bipolar Disorder drug therapy, Medication Adherence statistics & numerical data, Social Determinants of Health statistics & numerical data
- Abstract
Background: About 7 million people, 2.8% of US adults, have bipolar disorder (BD). While second-generation antipsychotics (SGA) are indicated as acute and maintenance treatments for BD, therapeutic success requires medication adherence and reported nonadherence estimates to range as high as 60%. Identifying patient risk factors for nonadherence is important for reducing it., Objective: The objective of this study was to quantify the associations of risk factors, including social determinants of health, with SGA nonadherence among patients with BD., Methods: In this cross-sectional study of 2015-2017 MassHealth Medicaid data, we examined several definitions of adherence and used logistic regression to identify risk factors for nonadherence (medication possession ratio <0.8) among all adults aged 18-64 diagnosed with BD who could be followed for 12 months following SGA initiation., Results: Among 5197 patients, the mean (±SD) age was 37.7 (±11.4) years, and 42.3% were men. Almost half (47.7%) of patients were nonadherent to SGAs when measured by medication possession ratio. The prevalence of nonadherence peaked at middle age for men and younger for women. Nonadherence was less common among Massachusetts' Department of Mental Health clients (odds ratio=0.60, 95% confidence limit: 0.48-0.74) and among those who used other psychotropic medications (odds ratios between 0.45 and 0.81); in contrast, increase in neighborhood socioeconomic stress was associated with increased odds of nonadherence., Conclusions/implications: Adherence to SGA treatment is suboptimal among people with BD. Recognizing risk factors, including those related to social determinants of health, can help target interventions to improve adherence for people at high risk and has implications for adherence-based quality measures., Competing Interests: The authors declare no conflict of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
37. Prevalence and the factors associated with oral anticoagulant use among nursing home residents.
- Author
-
Chen Q, Lapane K, Nunes AP, Tjia J, Hugunin J, and Alcusky M
- Subjects
- Aged, Aged, 80 and over, Body Mass Index, Cognition Disorders, Comorbidity, Drug Utilization, Fee-for-Service Plans, Female, Humans, Life Expectancy, Male, Medicare, Physical Functional Performance, Sociodemographic Factors, United States, Anticoagulants administration & dosage, Homes for the Aged statistics & numerical data, Nursing Homes statistics & numerical data
- Abstract
What Is Known and Objective: Anticoagulants are indicated for treatment and prevention of several clinical conditions. Prior studies have examined anticoagulant utilization for specific indications and in community-dwelling populations. Decision-making regarding anticoagulant prescribing in the nursing home setting is particularly challenging because advanced age and clinical complexity places most residents at increased risk for adverse drug events. To estimate the prevalence of oral anticoagulant (OAC) use (overall, warfarin, direct oral anticoagulants (DOACs)) and identify factors associated with oral anticoagulant use among the general population of residents living in nursing homes., Methods: This point prevalence study was conducted among 506,482 residents in US nursing homes on 31 October 2016 who were enrolled in Medicare fee-for-service. Covariates including demographics, clinical conditions, medications, cognitive impairment and functional status were obtained from Minimum Data Set 3.0 assessments and Medicare Part A and D claims. Oral anticoagulant use was identified using dispensing dates and days supply information from Medicare Part D claims. Robust Poisson models estimated adjusted prevalence ratios (aPR) for associations between covariates and 1) any anticoagulant use, and 2) DOAC versus warfarin use., Results and Discussion: Overall, 11.8% of residents used oral anticoagulants. Among users, 44.3% used DOACs. Residents with body mass index (BMI) ≥40 kg/m
2 (aPR: 1.66; 95% CI: 1.61 -1.71), with functional dependency in activities of daily living, polypharmacy and higher CHA2 DS2 -VASc risk ischaemic stroke scores, had a higher prevalence of oral anticoagulant use. Women (aPR: 0.78; 95% CI: 0.76-0.79), residents with limited life expectancy (aPR 0.80; 95% CI: 0.76-0.83), those with moderate-to-severe cognitive impairment (aPR: 0.67; 95% CI: 0.65-0.68), those using NSAIDs or antiplatelets, and non-white racial/ethnic groups had a lower prevalence of anticoagulant use. Residents with higher levels of polypharmacy, BMI and age had a lower prevalence of DOAC use (versus warfarin)., What Is New and Conclusion: Approximately one in eight general nursing home residents use oral anticoagulants and among oral anticoagulant users, only slightly more residents used warfarin than DOACs. The lower prevalence of anticoagulation among women and non-white racial/ethnic groups raises concerns of potential inequities in quality of care. Lower oral anticoagulant use among residents with limited life expectancy suggests possible deprescribing at the end of life. Further research is needed to inform resident-centred shared decision-making that explicitly considers treatment goals and individual-specific risks and benefits of anticoagulation at all stages of the medication use continuum., (© 2021 John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF
38. Barriers and Facilitators to Implementation of Value-Based Care Models in New Medicaid Accountable Care Organizations in Massachusetts: A Study Protocol.
- Author
-
Goff SL, Gurewich D, Alcusky M, Kachoria AG, Nicholson J, and Himmelstein J
- Subjects
- Administrative Personnel, Health Care Reform, Humans, Massachusetts, Medicaid, United States, Accountable Care Organizations
- Abstract
Introduction: Massachusetts established 17 new Medicaid accountable care organizations (ACOs) and 24 affiliated Community Partners (CPs) in 2018 as part of a large-scale healthcare reform effort to improve care value. The new ACOs will receive $1.8 billion dollars in state and federal funding over 5 years through the Delivery System Reform Incentive Program (DSRIP). The multi-faceted study described in this protocol aims to address gaps in knowledge about Medicaid ACOs' impact on healthcare value by identifying barriers and facilitators to implementation and sustainment of the DSRIP-funded programs. Methods and analysis: The study's four components are: (1) Document Review to characterize the ACOs and CPs; (2) Semi-structured Key Informant Interviews (KII) with ACO and CP leadership, state-level Medicaid administrators, and patients; (3) Site visits with selected ACOs and CPs; and (4) Surveys of ACO clinical teams and CP staff. The Consolidated Framework for Implementation Research's (CFIR) serves as the study's conceptual framework; its versatile menu of constructs, arranged across five domains (Intervention Characteristics, Inner Setting, Outer Setting, Characteristics of Individuals, and Processes) guides identification of barriers and facilitators across multiple organizational contexts. For example, KII interview guides focus on understanding how Inner and Outer Setting factors may impact implementation. Document Review analysis includes extraction and synthesis of ACO-specific DSRIP-funded programs (i.e., Intervention Characteristics); KIIs and site visit data will be qualitatively analyzed using thematic analytic techniques; surveys will be analyzed using descriptive statistics (e.g., counts, frequencies, means, and standard deviations). Discussion: Understanding barriers and facilitators to implementing and sustaining Medicaid ACOs with varied organizational structures will provide critical context for understanding the overall impact of the Medicaid ACO experiment in Massachusetts. It will also provide important insights for other states considering the ACO model for their Medicaid programs. Ethics and dissemination: IRB determinations were that the overall study did not constitute human subjects research and that each phase of primary data collection should be submitted for IRB review and approval. Study results will be disseminated through traditional channels such as peer reviewed journals, through publicly available reports on the mass.gov website; and directly to key stakeholders in ACO and CP leadership., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer DR declared a shared affiliation, with no collaboration, with one of the authors, DG to the handling editor at the time of the Review., (Copyright © 2021 Goff, Gurewich, Alcusky, Kachoria, Nicholson and Himmelstein.)
- Published
- 2021
- Full Text
- View/download PDF
39. Will the COVID-19 Pandemic Finally Fuel Drug Repurposing Efforts?
- Author
-
Chen A, Patel S, Alcusky M, and Maio V
- Subjects
- Big Data, Cooperative Behavior, Electronic Health Records statistics & numerical data, Genomics, Humans, Interinstitutional Relations, Pandemics, Proteomics, Registries statistics & numerical data, Research Design, SARS-CoV-2, COVID-19 epidemiology, Drug Repositioning methods
- Published
- 2021
- Full Text
- View/download PDF
40. Should Medicare Advantage Plans Receive Billions in Additional Risk-based Payments for Potentially Unmanaged Conditions?
- Author
-
Alcusky M and Mick EO
- Subjects
- Aged, Fee-for-Service Plans, Humans, Managed Care Programs, United States, Medicare Part C
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2021
- Full Text
- View/download PDF
41. Geographic Variation in Anticoagulant Use and Resident, Nursing Home, and County Characteristics Associated With Treatment Among US Nursing Home Residents.
- Author
-
Alcusky M, Baek J, Tjia J, McManus DD, and Lapane KL
- Subjects
- Aged, Anticoagulants, Cross-Sectional Studies, Humans, Nursing Homes, United States, Atrial Fibrillation drug therapy, Medicare
- Abstract
Objectives: To quantify geographic variation in anticoagulant use and explore what resident, nursing home, and county characteristics were associated with anticoagulant use in a clinically complex population., Design: A repeated cross-sectional design was used to estimate current oral anticoagulant use on December 31, 2014, 2015, and 2016., Setting and Participants: Secondary data for United States nursing home residents during the period 2014-2016 were drawn from the Minimum Data Set 3.0 and Medicare Parts A and D. Nursing home residents (≥65 years) with a diagnosis of atrial fibrillation and ≥6 months of Medicare fee-for-service enrollment were eligible for inclusion. Residents in a coma or on hospice were excluded., Methods: Multilevel logistic models evaluated the extent to which variation in anticoagulant use between counties could be explained by resident, nursing home, and county characteristics and state of residence. Proportional changes in cluster variation (PCVs), intraclass correlation coefficients (ICCs), and adjusted odds ratios (aORs) were estimated., Results: Among 86,736 nursing home residents from 11,860 nursing homes and 1694 counties, 45% used oral anticoagulants. The odds of oral anticoagulant use were 18% higher in 2016 than 2014 (aOR: 1.18; 95% confidence interval: 1.14-1.22). Most states had counties in the highest (51.3-58.9%) and lowest (31.1%-41.4%) deciles of anticoagulant use. Compared with the null model, adjustment for resident characteristics explained one-third of the variation between counties (PCV: 34.8%). The full model explained 65.5% of between-county variation. Within-county correlation was a small proportion (ICC < 2.2%) of total variation., Conclusions and Implications: In this older adult population at high risk for ischemic stroke, less than half of the residents received treatment with anticoagulants. Variation in treatment across counties was partially attributable to the characteristics of residents, nursing homes, and counties. Comparative evidence and refinement of predictive algorithms specific to the nursing home setting may be warranted., (Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. Calibrating Medicaid payment to need for long-term services and supports.
- Author
-
Alcusky M, Mick EO, Clark MA, and Ash AS
- Subjects
- Aged, Child, Humans, Massachusetts, Medicare, Motivation, United States, Activities of Daily Living, Medicaid
- Abstract
Objectives: The Massachusetts Medicaid and Children's Health Insurance Program, MassHealth, offers comprehensive Senior Care Options (SCO) plans to its Medicare-eligible members 65 years and older. Historically, MassHealth has paid a fixed per-person capitation rate for any "nursing home-certifiable" SCO member despite considerable heterogeneity of need. Our objective was to develop a model to predict long-term services and supports (LTSS) costs for community-dwelling SCO members., Study Design: Concurrent predictive modeling., Methods: We studied nursing home-certifiable SCO members who were enrolled for at least 183 days during 2016-2017 and used linear models to predict annual cost of community-based LTSS from demographic, medical, social determinants of health, and functional characteristics. We evaluated model performance using predictive performance (R2) and predictive ratios (observed costs divided by predicted costs) for various vulnerable subgroups., Results: The modeling population included 35,259 enrollees. Mean (SD) annualized LTSS cost was $14,071 ($13,174). Functional status (ie, activities of daily living [ADLs] and instrumental ADLs) accounted for most of the variability in community LTSS cost (R2 = 18.4%) explainable by available variables. The Massachusetts SCO (MA-SCO) model (R2 = 21.6%) predicts accurately for several high-cost, vulnerable subgroups. Compared with fixed per-member capitation payments for all, the MA-SCO model reduces, for example, the payment to one plan by 28% and increases that to another by 35%., Conclusions: Predictive models using administrative data and functional status information can appropriately allocate payments for subgroups of members with LTSS needs that differ substantially from average. Calibrating payment to need mitigates incentives for population skimming and promotes the sustainability of mission-oriented organizations.
- Published
- 2020
- Full Text
- View/download PDF
43. Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents.
- Author
-
Alcusky M, Tjia J, McManus DD, Hume AL, Fisher M, and Lapane KL
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, Anticoagulants adverse effects, Cohort Studies, Factor Xa Inhibitors, Humans, Medicare, Nursing Homes, Retrospective Studies, Treatment Outcome, United States epidemiology, Warfarin adverse effects, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Stroke epidemiology, Stroke prevention & control
- Abstract
Background: Research comparing direct-acting oral anticoagulants (DOACs) to warfarin has excluded nursing home residents, a vulnerable and high-risk population., Objective: To compare the safety and effectiveness of DOACs versus warfarin., Design: New-user cohort study (2011-2016)., Patients: US nursing home residents aged > 65 years with non-valvular atrial fibrillation enrolled in fee-for-service Medicare for > 6 months., Exposures: Initiators of DOACs (2881 apixaban, 1289 dabigatran, 3735 rivaroxaban) were 1:1 propensity matched to warfarin initiators., Main Measures: Outcomes included ischemic stroke or transient ischemic attack (i.e., ischemic cerebrovascular event), bleeding (extracranial or intracranial), other vascular events, death, and a composite of all outcomes. Absolute rate differences (RD) and cause-specific hazard ratios (HR) with 95% confidence intervals (CI) were estimated. Subgroup analyses were performed by alignment of DOAC dosing with labeling., Key Results: Median age (84 years), CHA
2 DS2 -Vasc (5), and ATRIA risk scores (3) were similar across medications. Clinical outcome rates were similar for dabigatran and rivaroxaban users versus warfarin users. However, ischemic cerebrovascular event rates were higher among dabigatran and rivaroxaban users that received reduced dosages without an indication. Overall, apixaban users had higher ischemic cerebrovascular event rates (HR 1.86; 95% CI 1.00-3.45) and lower bleeding rates (HR 0.66; 95% CI 0.49-0.88), but outcome rates varied by dosing alignment. Mortality rates (per 100 person-years) were lower for apixaban (RDs - 9.30; 95% CI - 13.18 to - 5.42), dabigatran (RDs - 10.79; 95% CI - 14.98 to - 6.60), and rivaroxaban (RDs - 8.92; 95% CI - 12.01 to - 5.83) versus warfarin; composite outcome findings were similar., Conclusions: Among US nursing home residents, the DOACs were each associated with lower mortality versus warfarin. Misaligned DOAC dosing was common in nursing homes and was associated with clinical and mortality outcomes. Overall, DOAC users had lower rates of adverse outcomes including mortality compared with warfarin users.- Published
- 2020
- Full Text
- View/download PDF
44. Evaluation of Care Processes and Health Care Utilization in Newly Implemented Medical Homes in Italy: A Population-Based Cross-sectional Study.
- Author
-
Alcusky M, Singer D, Keith SW, Hegarty SE, Lombardi M, Saccenti E, and Maio V
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Cross-Sectional Studies, Emergency Service, Hospital statistics & numerical data, Female, Health Services Research, Hospitalization statistics & numerical data, Humans, Italy, Male, Middle Aged, Process Assessment, Health Care, Quality Indicators, Health Care, Residence Characteristics, Sex Factors, Socioeconomic Factors, Young Adult, Ambulatory Care organization & administration, Patient Acceptance of Health Care statistics & numerical data, Patient-Centered Care organization & administration
- Abstract
In the Local Health Authority (LHA) of Parma, Emilia Romagna, Italy, 16 medical homes were established between 2011 and 2014. The authors implemented a 1-year (January 1, 2015, to December 31, 2015) cross-sectional population-based design to compare utilization and processes of care between medical homes and comparison practices using the Parma LHA administrative health care database. Residents (n = 372 396) attributed to a primary care physician practicing in a medical home as of January 1, 2015, were considered exposed to medical homes. Adjusted rates of emergency department (ED) use (incidence rate ratio [IRR] = 0.86; 95% CI = 0.82-0.90), potentially avoidable ED use (IRR = 0.78; 95% CI = 0.72-0.84), and hospitalization for chronic ambulatory care sensitive conditions (ACSCs; IRR = 0.87, 95% CI = 0.78-0.97) were lower among patients in medical homes. Performance on process of care measures favored the medical home group; however, associations were generally weak. Receipt of care in medical homes in Parma LHA was associated with lower rates of avoidable ED visits and hospitalizations for chronic ACSCs.
- Published
- 2020
- Full Text
- View/download PDF
45. Metformin exposure and survival in head and neck cancer: A large population-based cohort study.
- Author
-
Alcusky M, Keith SW, Karagiannis T, Rabinowitz C, Louis DZ, and Maio V
- Subjects
- Aged, Female, Humans, Italy, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms mortality, Hypoglycemic Agents adverse effects, Hypoglycemic Agents therapeutic use, Metformin adverse effects, Metformin therapeutic use
- Abstract
What Is Known and Objective: Observational clinical studies of metformin for prevention and treatment of several cancer types have reported mixed findings. Although preclinical studies have suggested metformin may reduce head and neck cancer (HNC) proliferation, clinical evidence is limited. The objective of this large population-based study was to evaluate the relationship between metformin exposure following HNC diagnosis and all-cause mortality., Methods: We conducted a retrospective cohort study using the Italian Emilia-Romagna Regional administrative healthcare database, which includes demographic, hospital and outpatient prescription information for ~4.5 million residents. Included patients were followed from the first hospital discharge (index) during the study period (01/2003-12/2012) with a diagnosis of HNC. Metformin exposure and select covariates were operationalized in a time-dependent manner during follow-up. Cox proportional hazards models estimated the covariate-adjusted time-dependent association between metformin exposure and all-cause mortality., Results and Discussion: Among 7872 patients diagnosed with HNC, 708 (9.0%) were exposed to metformin after HNC diagnosis, and 3626 (46.1%) died during follow-up (median follow-up: 35.2 months). In the covariate-adjusted model, the all-cause mortality rate appeared lower (HR: 0.81, 95% CI: 0.61-1.09) among metformin exposed patients during the 2 years post-diagnosis, while the all-cause mortality rate appeared higher (HR: 1.20, 95% CI: 0.94-1.53) among exposed patients after 2 years post-diagnosis. Metformin was protective among patients ≤60 years of age (HR for the period of 0-2 years post-diagnosis: 0.22, 95% CI 0.09-0.56; HR for the period ≥2 years post-diagnosis: 0.56, 95% CI 0.26-1.22) but not in those >60 years., What Is New and Conclusion: In this population-based study of metformin in HNC, we found a modest protective association between metformin exposure and all-cause mortality in the 2-year post-diagnosis period. Age appeared to modify the association between metformin and HNC survival., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
46. Letter by Jayaraman et al Regarding Articles, "Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants" and "Effectiveness and Safety of Oral Anticoagulants among Nonvalvular Atrial Fibrillation Patients: The ARISTOPHANES Study".
- Author
-
Jayaraman DK, Alcusky M, and Moonis M
- Subjects
- Anticoagulants, Humans, Incidence, Atrial Fibrillation, Brain Ischemia, Stroke
- Published
- 2019
- Full Text
- View/download PDF
47. Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016.
- Author
-
Alcusky M, McManus DD, Hume AL, Fisher M, Tjia J, and Lapane KL
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, Anticoagulants adverse effects, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Brain Ischemia diagnosis, Brain Ischemia epidemiology, Cross-Sectional Studies, Drug Substitution trends, Drug Utilization trends, Factor Xa Inhibitors adverse effects, Female, Health Care Surveys, Hemorrhage chemically induced, Hemorrhage epidemiology, Humans, Male, Medicare trends, Risk Factors, Stroke diagnosis, Stroke epidemiology, Time Factors, Treatment Outcome, United States epidemiology, Anticoagulants administration & dosage, Atrial Fibrillation drug therapy, Brain Ischemia prevention & control, Factor Xa Inhibitors administration & dosage, Homes for the Aged trends, Nursing Homes trends, Practice Patterns, Physicians' trends, Stroke prevention & control, Warfarin therapeutic use
- Abstract
Background Nursing home residents with atrial fibrillation are at high risk for ischemic stroke and bleeding events. The most recent national estimate (2004) indicated less than one third of this high-risk population was anticoagulated. Whether direct-acting oral anticoagulant ( DOAC ) use has disseminated into nursing homes and increased anticoagulant use is unknown. Methods and Results A repeated cross-sectional design was used to estimate the point prevalence of oral anticoagulant use on July 1 and December 31 of calendar years 2011 to 2016 among Medicare fee-for-service beneficiaries with atrial fibrillation residing in long-stay nursing homes. Nursing home residence was determined using Minimum Data Set 3.0 records. Medicare Part D claims for apixaban, dabigatran, edoxaban, rivaroxaban, and warfarin were identified and point prevalence was estimated by determining if the supply from the most recent dispensing covered each point prevalence date. A Cochran-Armitage test was performed for linear trend in prevalence. On December 31, 2011, 42.3% of 33 959 residents (median age: 85; Q1 79, Q3 90) were treated with an oral anticoagulant, of whom 8.6% used DOAC s. The proportion receiving treatment increased to 47.8% of 37 787 residents as of December 31, 2016 ( P<0.01); 48.2% of 18 054 treated residents received DOAC s. Demographic and clinical characteristics of residents using DOAC s and warfarin were similar in 2016. Half of the 8734 DOAC users received standard dosages and most were treated with apixaban (54.4%) or rivaroxaban (35.8%) in 2016. Conclusions Increases in anticoagulant use among US nursing home residents with atrial fibrillation coincided with declining warfarin use and increasing DOAC use.
- Published
- 2019
- Full Text
- View/download PDF
48. Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities.
- Author
-
Alcusky M, Hume AL, Fisher M, Tjia J, Goldberg RJ, McManus DD, and Lapane KL
- Subjects
- Aged, Aged, 80 and over, Anticoagulants therapeutic use, Cohort Studies, Female, Hemorrhage chemically induced, Humans, Intracranial Hemorrhages chemically induced, Ischemic Attack, Transient drug therapy, Male, Medicare, Myocardial Infarction epidemiology, Proportional Hazards Models, Retrospective Studies, Secondary Prevention, Skilled Nursing Facilities, Thromboembolism prevention & control, United States, Atrial Fibrillation drug therapy, Dabigatran administration & dosage, Rivaroxaban administration & dosage, Stroke prevention & control
- Abstract
Background: Thromboembolic and bleeding risk are elevated in older patients with atrial fibrillation and prior stroke. We compared dabigatran with rivaroxaban for secondary prevention in a national population after skilled nursing facility (SNF) discharge., Methods: Medicare fee-for-service beneficiaries aged ≥ 65 years with atrial fibrillation hospitalized for ischemic stroke (November 2011-October 2013) and subsequently admitted to an SNF were studied. Dabigatran (n = 332) and rivaroxaban users (n = 378) were compared in a retrospective, active comparator, new-user cohort. The index medication claim occurred within 120 days after hospital discharge and exposure continued until a 14-day treatment gap ('as treated'). The primary net clinical benefit outcome was the time to recurrent stroke, transient ischemic attack, intracranial hemorrhage, extracranial bleed, myocardial infarction, venous thromboembolism, or death. All-cause mortality was evaluated separately as a secondary outcome. Multivariable adjusted Cox models stratified by dosage estimated hazard ratios (aHR)., Results: Among those receiving low dosages, the crude composite event rate was 40.4/100 person-years among dabigatran users and 33.7/100 person-years among rivaroxaban users. The composite outcome [aHR 1.48; 95% confidence interval (CI) 0.87-2.51] and all-cause mortality (aHR 1.67; 95% CI 0.84-3.31) rates were higher among low-dose dabigatran users. For those receiving standard doses, the crude composite event rates were 19.5/100 person-years for dabigatran users and 37.1/100 person-years for rivaroxaban users. Although no difference in mortality was observed, the composite outcome rate was lower among standard-dose dabigatran users (aHR 0.65; 95% CI 0.36-1.15)., Conclusions: In older adults treated with direct-acting oral anticoagulants after ischemic stroke, outcome rates varied considerably by drug and dosage.
- Published
- 2018
- Full Text
- View/download PDF
49. Geographic Variation in the Initiation of Commonly Used Opioids and Dosage Strength in United States Nursing Homes.
- Author
-
Hunnicutt JN, Baek J, Alcusky M, Hume AL, Liu SH, Ulbricht CM, Tjia J, and Lapane KL
- Subjects
- Aged, 80 and over, Cross-Sectional Studies, Female, Humans, Male, Nursing Homes organization & administration, Nursing Homes statistics & numerical data, Practice Patterns, Physicians' standards, United States, Analgesics, Opioid administration & dosage, Analgesics, Opioid therapeutic use, Geographic Mapping, Practice Patterns, Physicians' statistics & numerical data
- Abstract
Objectives: To examine and quantify geographic variation in the initiation of commonly used opioids and prescribed dosage strength among older US nursing home residents., Methods: We merged 2011 Minimum Data Set 3.0 to Medicare claims and facility characteristics data to conduct a cross-sectional study among long-stay nursing home residents who initiated short-acting opioids commonly used in nursing homes (oxycodone, hydrocodone, or tramadol). We examined geographic variation in specific opioids initiated and potentially inappropriate doses (≥50 mg oral morphine equivalent/d) across hospital referral regions (HRRs). Multilevel logistic models quantified the proportional change in between-HRR variation and associations between commonly initiated opioids and inappropriate doses after adjusting for resident characteristics, facility characteristics, and state., Results: Oxycodone (9.4%) was initiated less frequently than hydrocodone (56.2%) or tramadol (34.5%) but varied dramatically between HRRs (range, 0%-74.5%). In total, resident/facility characteristics and state of residence, respectively explained 84.1%, 58.2%, 59.1%, and 46.6% of the between-HRR variation for initiating oxycodone, hydrocodone, tramadol, and inappropriate doses. In all cases, state explained the largest proportion of between-HRR variation. Relative to hydrocodone, residents initiating oxycodone were more likely (adjusted odds ratio, 5.00; 95% confidence interval, 4.57-5.47) and those initiating tramadol were less likely (adjusted odds ratio, 0.28; 95% confidence interval, 0.25-0.31) to be prescribed potentially inappropriately high doses., Conclusions: We documented extensive geographic variation in the opioid and dose initiated for nursing home residents, with state explaining the largest proportion of the observed variation. Further work is needed to understand potential drivers of opioid prescribing patterns at the state level.
- Published
- 2018
- Full Text
- View/download PDF
50. Postacute Care Setting, Facility Characteristics, and Poststroke Outcomes: A Systematic Review.
- Author
-
Alcusky M, Ulbricht CM, and Lapane KL
- Subjects
- Age Factors, Cognition Disorders epidemiology, Disability Evaluation, Humans, Length of Stay, Patient Readmission statistics & numerical data, Sex Factors, Stroke Rehabilitation mortality, Time Factors, Treatment Outcome, Quality of Life, Rehabilitation Centers organization & administration, Skilled Nursing Facilities organization & administration, Stroke Rehabilitation statistics & numerical data, Subacute Care organization & administration
- Abstract
Objectives: To synthesize research comparing poststroke health outcomes between patients rehabilitated in skilled nursing facilities (SNFs) and those in inpatient rehabilitation facilities (IRFs) as well as to evaluate relations between facility characteristics and outcomes., Data Sources: PubMed and CINAHL searches spanned January 1, 1998, to October 6, 2016, and encompassed MeSH and free-text keywords for stroke, IRF/SNF, and study outcomes. Searches were restricted to peer-reviewed research in humans published in English., Study Selection: Observational and experimental studies examining outcomes of adult patients with stroke rehabilitated in an IRF or SNF were eligible. Studies had to provide site of care comparisons and/or analyses incorporating facility-level characteristics and had to report ≥1 primary outcome (discharge setting, functional status, readmission, quality of life, all-cause mortality). Unpublished, single-center, descriptive, and non-US studies were excluded. Articles were reviewed by 1 author, and when uncertain, discussion with study coauthors achieved consensus. Fourteen titles (0.3%) were included., Data Extraction: The types of data, time period, size, design, and primary outcomes were extracted. We also extracted 2 secondary outcomes (length of IRF/SNF stay, cost) when reported by included studies. Effect measures, modeling approaches, methods for confounding adjustment, and potential confounders were extracted. Data were abstracted by 1 author, and the accuracy was verified by a second reviewer., Data Synthesis: Two studies evaluating community discharge, 1 study evaluating the predicted probability of readmission, and 3 studies evaluating all-cause mortality favored IRFs over SNFs. Functional status comparisons were inconsistent. No studies evaluated quality of life. Two studies confirmed increased costs in the IRF versus SNF setting. Although substantial facility variation was described, few studies characterized sources of variation., Conclusions: The few studies comparing poststroke outcomes indicated better outcomes (with higher costs) for patients in IRFs versus those in SNFs. Contemporary research on the role of the postacute care setting and its attributes in determining health outcomes should be prioritized to inform reimbursement system reform., (Copyright © 2017 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.